Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 8/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | USP10 | Q14694 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | USP13 | Q92995 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27797765 | 0.86 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL4060831 | 0.86 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL496868 | 0.82 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL27890062 | 0.82 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL13404526 | 0.79 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL17209359 | 0.78 | PIK3CG (0.45) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL27868783 | 0.78 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL19032266 | 0.78 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL30405899 | 0.78 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL2642909 | 0.77 | ALDH1A1 (0.48) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-7361663-B2 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2005-07-28 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| EP-1451175-A1 | THROMBIN INHIBITORS | University of Ljubljana (SI) | 2004-09-01 | — | — | EP | disclosed |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| US-6602864-B1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| WO-2003048155-A1 | THROMBIN INHIBITORS | UNIVERSITY OF LJUBLJANA (SI) | 2003-06-12 | — | — | WO | disclosed |
| EP-0944386-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| CN-1244798-A | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | RHONE POULENC RORER PHARMA (US) | 2000-02-16 | — | — | CN | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0944386-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025611-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | PDE4A 645/4885PDE4B 523/4885PDE4C 975/4885 |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | PDE4A 1602/4885PDE4B 1561/4885PDE4C 995/4885 |
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | SERPINC1, TFPI, SERPINE1 | PDE4A 3264/4885PDE4B 3185/4885PDE4C 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.